Is JCR Pharmaceuticals Co., Ltd. (JCRRF) a Buy, Sell, or Hold?
OTC : JCRRF
JCR Pharmaceuticals Co., Ltd.
$3.31 USD
$0 (0.0%)
- Volume
- 476
- Average Volume
- 24
- Market Capitalization
- $403.8M
- P/E Ratio
- 28.60
- Dividend Yield
- 3.91%
- Price Target
- Year High
- $5.00
- Year Low
- $3.15
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.16
Company Overview
OTC
Toru Ashida
Drug Manufacturers - General
Healthcare
JCRRF
985
JP
USD
Liquidity Metrics
1.15
1.16
0.67
0.29
0.00
Sales & Valuation
$40.57B
1.55
1.33
0.00
0.00
Profitability
$17.58
$2.19B
5.40%
8.00%
4.64%
1.99%
P/E Metrics
28.60
0.11
0.11
Analyst Price Target & Rating
0/5
0 Analysts
%
Poll Results
About JCR Pharmaceuticals Co., Ltd. (OTC:JCRRF) Stock
JCR Pharmaceuticals Co., Ltd., a specialized pharmaceutical company headquartered in Ashiya, Japan, and established in 1975, operates across the entire lifecycle of pharmaceutical products, regenerative medicines, and active drug substances. Its comprehensive activities in Japan encompass research, development, manufacturing, and both the import, export, and sale of these medical items. The company's current therapeutic offerings include several key treatments: GROWJECT, utilized for patients suffering from growth hormone deficiency and short stature. IZCARGO, specifically designed to address Mucopolysaccharidosis type II. Agalsidase Beta BS I.V. Infusion, administered for the management of Fabry disease. TEMCELL HS Inj, employed in the treatment of acute graft-versus-host disease. Further ... more, JCR Pharmaceuticals is actively expanding its pipeline with the development of Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended to combat renal anemia. Beyond its pharmaceutical ventures, the firm also provides a selection of medical devices and laboratory instruments.
2026-06-17 12:30:00
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®
2026-06-08 13:34:00
HYOGO, Japan--(BUSINESS WIRE)--JCR presented new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases, held June 4-7, 2026.
2026-05-28 11:43:00
HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it will present new clinical data in a poster session at the 18th International Symposium on MPS and Related Lysosomal Diseases.
2026-05-18 12:58:00
HYOGO, Japan--(BUSINESS WIRE)--JCR announced today that it presented preclinical data from its novel platform technologies in oral and poster sessions at the ASGCT Annual Meeting.
2026-05-11 13:06:00
HYOGO, Japan--(BUSINESS WIRE)--JCR will present preclinical data from its novel platform technologies, including JUST-AAV gene therapy, at the ASGCT 29th Annual Meeting this week.
Frequently Asked Questions
-
What is the current JCR Pharmaceuticals Co., Ltd. (JCRRF) stock price?
-
JCR Pharmaceuticals Co., Ltd.(OTC:JCRRF) stock price is $3.31 in the last trading session. During the trading session, JCRRF stock reached the peak price of $5 while $3.145 was the lowest point it dropped to. The percentage change in JCRRF stock occurred in the recent session was 0.0% while the dollar amount for the price change in JCRRF stock was $0.
-
JCRRF's industry and sector of operation?
-
The OTC listed JCRRF is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of JCRRF?
-
Hiroyuki Fukuya | Exec Off, Dir of Legal & Compliance, Internal Control Dept and Chief Legal & Compliance Off
Tomohiko Miyagawa | Executive Officer and Executive Director of Sales Division
Katsuya Nishino | Executive Vice President
Hiroyuki Sonoda | President, Chief Scientific Officer & Representative Director
Shin Ashida | Founder & Director -
How many employees does JCRRF have?
-
Number of JCRRF employees currently stands at 985. JCRRF operates from 3-19 Kasuga-cho, Ashiya, HY 659-0021, JP.
-
Link for JCRRF official website?
-
Official Website of JCRRF is: https://www.jcrpharm.co.jp
-
How do I contact JCRRF?
-
JCRRF could be contacted at phone #81 7 9732 8591 and can also be accessed through its website. JCRRF operates from 3-19 Kasuga-cho, Ashiya, HY 659-0021, JP.
-
How many shares of JCRRF are traded daily?
-
The average number of JCRRF shares traded daily for last 3 months was 24.
-
What is the market cap of JCRRF currently?
-
The market value of JCRRF currently stands at $403.8M with its latest stock price at $3.31